Yes, title and abstract are below. 

Optical metabolic imaging predicts anti-cancer therapeutic response

The drug combination that is chosen for cancer patients is determined from histological markers of receptor expression.  Unfortunately, many patients do not respond to chemotherapy, and therefore face a greater risk of recurrence and death.  No current technologies can accurately predict individual tumor response to particular drugs.  Cellular metabolism is a potentially powerful marker of tumor response to treatment, because the oncogenic drivers targeted by therapeutic agents often regulate cellular metabolism.  In this study, we demonstrate the sensitivity of optical metabolic imaging to predict therapeutic response in xenografts in vivo, and in primary patient tumor derived organoids, in both breast cancer and pancreatic cancer models.  We utilize mulitphoton fluorescence intensity and fluorescence lifetime imaging to probe cellular NADH and FAD, two coenzymes of metabolism.   Endpoints of cellular metabolism include the optical redox ratio (NADH fluorescence intensity divided by that of FAD) the mean fluorescence lifetime of NADH, and the mean fluorescence lifetime of FAD.  Upon treatment with estrogen receptor inhibitors and human epidermal growth factor receptor inhibitors, the redox ratio of responsive tumors decreases (p<0.001) and is further reduced when effective therapies are combined (p<0.001).  Furthermore, the NADH fluorescence lifetime decreases in organoids treated with human epidermal growth factor receptor inhibitors (p<0.05).  With these findings, optical metabolic imaging shows potential for development into a high-throughput screen to test the efficacy of a panel of drugs to direct clinical therapy selection and expedite pre-clinical studies.

Alex Walsh